SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 277.26 |
| Enterprise Value ($M) | 236.21 |
| Book Value ($M) | 110.28 |
| Book Value / Share | 0.80 |
| Price / Book | 2.51 |
| NCAV ($M) | 102.97 |
| NCAV / Share | 0.74 |
| Price / NCAV | 2.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.47 |
| Return on Assets (ROA) | -0.34 |
| Return on Equity (ROE) | -0.35 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.33 |
| Current Ratio | 8.33 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 124.14 |
| Assets | 131.45 |
| Liabilities | 21.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.85 |
| Operating Income | -56.62 |
| Net Income | -49.38 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -44.85 |
| Cash from Investing | 46.77 |
| Cash from Financing | 17.34 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Orbimed Advisors Llc | 11.00 | -19.01 | |
| 13G | MPM Oncology Impact Management LP | 6.20 | ||
| 13G/A | Adage Capital Partners Gp, L.l.c. | 4.36 | -39.32 | |
| 13G | BlackRock, Inc. | 5.00 | ||
| 13G | Tang Capital Management Llc | 5.40 | ||
| 13G/A | Janus Henderson Group Plc | 1.30 | -75.90 | |
| 13G | Blackstone Holdings II L.P. | 6.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 186,664 | 1,092,035 | 17.09 | |
| 269,932 | 1,575,796 | 17.13 | |
| 134,359 | 540,691 | 24.85 | |
| 200,222 | 1,416,415 | 14.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CLDX – Celldex Therapeutics, Inc. | CLNN – Clene Inc. |
| CLRB – Cellectar Biosciences, Inc. | CNSP – CNS Pharmaceuticals, Inc. |
| CNTX – Context Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io